All FDA-approved GLP-1 receptor agonists for weight management — semaglutide (Wegovy), tirzepatide (Zepbound) — carry a boxed warning derived from rodent studies showing thyroid C-cell tumors. The warning explicitly contraindicates use in patients with a personal or family history of MTC or MEN 2.
While the rodent finding has not translated to confirmed human risk, the FDA maintains the contraindication. If you have a personal or first-degree-relative history of either condition, discuss alternative options (orlistat, naltrexone-bupropion, bariatric surgery referral) with your clinician.